Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643667 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02643667 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 27 participants.
The verdict
NCT02643667, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP
Interventions
- DRUG Ibrutinib
- PROCEDURE Radical prostatectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-07 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643667
The ClinicalTrials.gov registry entry for NCT02643667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT02643667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643667 about?
NCT02643667 is a clinical study titled "Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer". 30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery ma...
What is the current status of trial NCT02643667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2016-07. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT02643667?
The interventions under investigation include: Ibrutinib (DRUG), Radical prostatectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02643667?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.